Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in the 20-Valent Pneumococcal Conjugate Vaccine in the Adult Population in France

Clicks: 22
ID: 319653
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #151 of 321 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 321 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Streptococcus pneumoniae causes invasive pneumococcal disease and pneumonia. This study models the burden of adult pneumococcal disease in France. Over a 5-year period, approximately 630,000 cases and €3.1 billion of costs were attributable to pneumococcus, mostly non-invasive disease, with nearly 80% due to serotypes included in 20-valent pneumococcal conjugate vaccine.
Reference Key
openalex_W7167360905 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag381
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.